Simultaneous determination of ornidazole and its main metabolites in human plasma by LC-MS/MS: Application to a pharmacokinetic study

Bioanalysis

Volumn 6, Issue 18, 2014, Pages 2343-2356

  Du, Jiangbo ^a   Ma, Zhiyu ^a   Zhang, Yifan ^a   Wang, Ting ^b   Chen, Xiaoyan ^a   Zhong, Dafang ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b LANZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; ORNIDAZOLE;

ADULT; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CORRELATION COEFFICIENT; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PURIFICATION; DRUG SPECIFICITY; DRUG STABILITY; DRUG SYNTHESIS; ELECTROSPRAY; GLUCURONIDATION; HUMAN; HUMAN EXPERIMENT; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PILOT STUDY; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VALIDATION PROCESS; BLOOD; BLOOD ANALYSIS; CLINICAL TRIAL; LIQUID CHROMATOGRAPHY; METABOLISM; PROCEDURES; STATISTICAL MODEL; TIME; YOUNG ADULT;

ADULT; BLOOD CHEMICAL ANALYSIS; CHROMATOGRAPHY, LIQUID; HUMANS; LIMIT OF DETECTION; LINEAR MODELS; MALE; ORNIDAZOLE; TANDEM MASS SPECTROMETRY; TIME FACTORS; YOUNG ADULT;

EID: 84922637051     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.14.117     Document Type: Article

References (35)

1. Singh P, Mittal R, Sharma GC et al. Ornidazole: comprehensive profile. Profiles Drug Subst. Excip. Relat. Methodol. 30, 123-184 (2003).
2. Kedderis GL, Argenbright LS, Miwa GT. Covalent interaction of 5-nitroimidazoles with DNA and protein in vitro: mechanism of reductive activation. Chem. Res. Toxicol. 2(3), 146-149 (1989).
3. Müller M. Mode of action of metronidazole on anaerobic bacteria and protozoa. Surgery 93(1 Pt 2), 165-171 (1983).
4. Edwards DI. Mechanism of antimicrobial action of metronidazole. J. Antimicrob. Chemother. 5(5), 499-502 (1979).
5. Schwartz DE, Jeunet F. Comparative pharmacokinetic studies of ornidazole and metronidazole in man. Chemotherapy 22(1), 19-29 (1976).
6. Wüst J. Susceptibility of anaerobic bacteria to metronidazole, ornidazole, and tinidazole and routine susceptibility testing by standardized methods. Antimicrob. Agents Chemother. 11(4), 631-637 (1977).
7. Goldstein EJ, Sutter VL, Finegold SM. Comparative susceptibilities of anaerobic bacteria to metronidazole, ornidazole, and SC-28538. Antimicrob. Agents Chemother. 14(4), 609-613 (1978).
8. Du JB, You TG, Chen XY et al. Stereoselective glucuronidation of ornidazole in humans: predominant contribution of UDP-glucuronosyltransferases 1A9 and 2B7. Drug Metab. Dispos. 41(7), 1306-1318 (2013).
9. Loi CM, Smith DA, Dalvie D. Which metabolites circulate Drug Metab. Dispos. 41(5), 933-951 (2013).
10. Hoffer M, Grunberg E. Synthesis and antiprotozoal activity of 1-(3-chloro-2-hydroxypropyl)-substituted nitroimidazoles. J. Med. Chem. 17(9), 1019-1020 (1974).
11. Li LC: CN101161644A (2008).
12. Armstrong RN. Kinetic and chemical mechanism of epoxide hydrolase. Drug Metab. Rev. 31(1), 71-86 (1999).
13. Armstrong RN, Cassidy CS. New structural and chemical insight into the catalytic mechanism of epoxide hydrolases. Drug Metab. Rev. 32(3-4), 327-338 (2000).
14. Arand M, Cronin A, Oesch F et al. The telltale structures of epoxide hydrolases. Drug Metab. Rev. 35(4), 365-383 (2003).
15. Du JB, Ma ZY, Zhang YF et al. Enantioselective determination of ornidazole in human plasma by liquid chromatography-tandem mass spectrometry on a Chiral-AGP column. J. Pharm. Biomed. Anal. 86, 182-188 (2013).
16. Desilva JA, Munno N, Strojny N. Absorptiometric, polarographic, and gas chromatographic assays for the determination of N-1-substituted nitroimidazoles in blood and urine. J. Pharm. Sci. 59(2), 201-210 (1970).
17. Brooks MA, D'Arconte L, De Silva JA. Determination of nitroimidazoles in biological fluids by differential pulse polarography. J. Pharm. Sci. 65(1), 112-114 (1976).
18. Bhatia SC, Shanbhag VD. Electron-capture gas chromatographic assays of 5-nitroimidazole class of antimicrobials in blood. J. Chromatogr. 305(2), 325-334 (1984).
19. Zhang LY, Zhang ZJ, Wu K. In vivo and real time determination of ornidazole and tinidazole and pharmacokinetic study by capillary electrophoresis with microdialysis. J. Pharm. Biomed. Anal. 41(4), 1453-1457 (2006).
20. Merdjan H, Bonnat C, Singlas E et al. Measurement of ornidazole by high-performance liquid chromatography. J. Chromatogr. 273(2), 475-480 (1983).
21. Groppi A, Papa P, Montagna M et al. Determination of ornidazole in human plasma and red blood cells using highperformance liquid chromatography. J. Chromatogr. 380(2), 437-442 (1986).
22. Rona K, Gachalyi B. Simple liquid chromatographic method for the determination of ornidazole and metronidazole in human serum. J. Chromatogr. 420(1), 228-230 (1987).
23. Wang YQ, Zhang PP, Jiang NL et al. Simultaneous quantification of metronidazole, tinidazole, ornidazole and morinidazole in human saliva. J. Chromatogr. B 899, 27-30 (2012).
24. Cronly M, Behan P, Foley B et al. Development and validation of a rapid method for the determination and confirmation of nitroimidazoles in animal plasma using liquid chromatography tandem mass spectrometry. J. Chromatogr. B 877(14-15), 1494-1500 (2009).
25. Du JB, Deng P, Chen XY et al. Characterization of ornidazole metabolites in human bile after intraveneous doses by ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry. Acta Pharma. Sin. B 2(2), 159-167 (2012).
26. Heizmann P, Geschke R, Zinapold K. Determination of ornidazole and its main metabolites in biological fluids. J. Chromatogr. 534, 233-240 (1990).
27. US FDA. Guidance for Industry: Bioanalytical Method Validation (2013). www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM368107.pdf
28. EMA. Guideline on Bioanalytical Method Validation (2011). www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2011/08/WC500109686.pdf
29. Freisleben A, Brudny-Kloppel M, Mulder H et al. Blood stability testing: European Bioanalysis Forum view on current challenges for regulated bioanalysis. Bioanalysis 3(12), 1333-1336 (2011).
30. Lowes S, Jersey J, Shoup R et al. Recommendations on: internal standard criteria, stability, incurred sample reanalysis and recent 483s by the Global CRO Council for Bioanalysis. Bioanalysis 3(12), 1323-1332 (2011).
31. Jemal M, Xia YQ. Bioanalytical method validation design for the simultaneous quantitation of analytes that may undergo interconversion during analysis. J. Pharm. Biomed. Anal. 22(5), 813-827 (2000).
32. Rocci ML, Devanarayan V, Haughey DB et al. Confirmatory reanalysis of incurred bioanalytical samples. AAPS J. 9(3), E336-E343 (2007).
33. Yadav M, Shrivastav PS. Incurred sample reanalysis (ISR): a decisive tool in bioanalytical research. Bioanalysis 3(9), 1007-1024 (2011).
34. Sangster T, Maltas J, Struwe P et al. Recommendations on ISR in multianalyte assays, QA/bioanalytical consultants and GCP by Global CRO Council for Bioanalysis (GCC). Bioanalysis 4(14), 1723-1730 (2012).
35. Cote C, Bergeron A, Mess JN et al. Matrix effect elimination during LC-MS/MS bioanalytical method development. Bioanalysis 1(7), 1243-1257 (2009).